These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2060550)

  • 21. Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy.
    Mitrovic V; Gessner C; Hain P; Müller KD; Schlepper M
    Clin Cardiol; 1991 Mar; 14(3):209-18. PubMed ID: 1672843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronopharmacokinetics and cardiovascular effects of nifedipine.
    Lemmer B; Nold G; Behne S; Kaiser R
    Chronobiol Int; 1991; 8(6):485-94. PubMed ID: 1799930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.
    Straehl P; Galeazzi RL; Soliva M
    Clin Pharmacol Ther; 1984 Oct; 36(4):485-92. PubMed ID: 6478734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
    Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
    Arzneimittelforschung; 1998 Jun; 48(6):641-5. PubMed ID: 9689420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
    Skutta T; Böttcher B; Brandt L
    Arzneimittelforschung; 1989 Apr; 39(4):507-11. PubMed ID: 2751738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between the pharmacodynamics and pharmacokinetics of two oral sustained-release formulations of isosorbide dinitrate in normal man.
    Johnson KI; Gladigau V; Schnelle K
    Arzneimittelforschung; 1981; 31(6):1026-9. PubMed ID: 7196234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of GSTM1 null polymorphism with isosorbide-5-mononitrate cardiovascular response and involvement of CGRP in healthy Chinese male volunteers.
    Guo R; Chen L; Li L; Guo X; Sun J; Xiong XM; Cheng ZN; Li YJ; Chen XP
    Pharmacogenet Genomics; 2011 Mar; 21(3):142-51. PubMed ID: 21278620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
    Parker JO
    Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of intravenous and oral isosorbide - 5 - mononitrate.
    Abshagen U; Betzien G; Endele R; Kaufmann B
    Eur J Clin Pharmacol; 1981; 20(4):269-75. PubMed ID: 7308280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
    Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM
    Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of tolerance after chronic administration of controlled-release isosorbide-5-mononitrate. Interaction of nitrate and gallopamil.
    Stauch M; Grossmann G; Wanjura D; Adam WE
    Eur J Clin Pharmacol; 1990; 38 Suppl 1():S31-4. PubMed ID: 2354712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration.
    Vogt D; Trenk D; Bonn R; Jähnchen E
    Eur J Clin Pharmacol; 1994; 46(4):319-24. PubMed ID: 7957516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic aspects of isosorbide-5-mononitrate in dogs.
    Sponer G; Kühnle HF; Strein K; Bartsch W; Endele R; Dietmann K
    J Pharmacol Exp Ther; 1984 Jan; 228(1):235-9. PubMed ID: 6694105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].
    Rietbrock N; Knoll J; Merz PG; Menke G
    Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
    Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
    Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A sustained release formulation of isosorbide-5-mononitrate with a rapid onset of action.
    Arthur RM; Mehmel H
    Int J Clin Pract; 1999; 53(3):205-12. PubMed ID: 10665134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bioavailability of delayed-action and non-delayed-action preparations of isosorbide-5-nitrate].
    Heidemann R; Gracien E; Menke G; Rietbrock N
    Dtsch Med Wochenschr; 1987 May; 112(18):719-22. PubMed ID: 3569063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of isosorbide-5-mononitrate, a major metabolite of isosorbide dinitrate (ISDN), to the hemodynamic effect of ISDN administered orally in conscious dogs.
    Kogi K; Satoh T
    Jpn J Pharmacol; 1987 Jul; 44(3):249-57. PubMed ID: 3656782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of an oral dose of isosorbide dinitrate on platelet function and fibrinolysis in healthy volunteers.
    Wallén NH; Larsson PT; Bröijersén A; Andersson A; Hjemdahl P
    Br J Clin Pharmacol; 1993 Feb; 35(2):143-51. PubMed ID: 8443032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the pharmacokinetics and absolute bioavailability of three isosorbide-5-mononitrate preparations in healthy volunteers.
    Hutt V; Bonn R; Fritschi E; Jaeger H
    Arzneimittelforschung; 1995 Feb; 45(2):142-5. PubMed ID: 7710435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.